A little more than two months after launching with a $55 million bankroll and a plan to develop next-gen cancer vaccines and immunotherapies, Third Rock startup Neon Therapeutics has allied with a leader in the checkpoint inhibitor space.
Bayer HealthCare has taken full control of the development of CGEN-15001T, an immune checkpoint inhibitor discovered by Compugen. The asset transfer triggered a $7.8 million (€7.1 million) milestone payment by Bayer, bringing the total pocketed by Compugen since it entered into the deal in 2013 up to $25 million.
Three months after reassuring investors with upbeat Phase II data for its lead drug, Akebia has inked a $350 million Asian deal on the therapy, gaining a $40 million upfront and $60 million more in cash support for the pivotal study.
The U.S. subsidiary of Beijing-based Yisheng Biopharma will work with the U.S. Army Medical Research Institute of Infectious Diseases to develop a new Ebola vaccine.
Medtronic isn't exactly a consumer brand. But it's hoping that extending a partnership with Samsung will help it integrate its existing, extensive medical device portfolio with ubiquitous consumer smart devices. In June, the pair announced a partnership to do just that in diabetes and now they're expanding that deal into neuromodulation devices.
Geneva-based Gavi, the global vaccine alliance funded by the Bill and Melinda Gates Foundation and other donors, has pledged $500 million over the next 5 years to support India's country-wide immunization program.
Sun Pharmaceutical of India has signed a deal with an institute in Israel and one in Spain to develop treatments for neurological diseases like strokes and the brain cancer glioblastoma.
CRO Charles River Laboratories has expanded its relationship with the Michael J. Fox Foundation for Parkinson's Research to investigate a promising target that could lead to new treatments for the disease.
Researchers in China and New Zealand have teamed up to develop a research program that will try to improve research initiatives "biomedicine, engineering sciences, and systems to support innovation and commercialization," according to a recent report.
China's WuXi PharmaTech and North Carolina-based PRA Health Sciences said they have reorganized their joint operations in China, Hong Kong and Macau that were originally formed in 2013.